Urofi

This is the combination of Finasteride, a specific inhibitor of steroid Type II 5a-reductase and Tadalafil, a selective inhibitor of phosphodiesterase type-5 (PDE5).

Finasteride is a specific inhibitor of steroid Type II 5a-reductase which is an intracellular enzyme that converts the androgen testosterone into 5 a-dihydrotestosterone (DHT). Finasteride lowers the level of DHT hormone (dihydrotestosterone), which is a cause of prostate growth. Lowering DHT leads to shrinkage of the enlarged prostate gland in men.

Tadalafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Tadalafil may reduce Benign Prostatic Hyperplasia (BPH) symptoms by inhibiting the action of an enzyme called PDE5 (phosphodiesterase 5), which relaxes the smooth muscles of the prostate that surrounds the urethra resulting in the release of the restriction to the flow of urine through the urethra.

Nitrates: Administration of this capsule to patients who are using any form of organic nitrate, is contraindicated. In clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates.

Alpha-Blockers: Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. Discontinuation of alpha-blockers is recommended at least one day prior to starting this capsule for once-daily use for the treatment of BPH.

Antihypertensives: PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents (amlodipine, angiotensin II receptor blockers, bendrofluazide, enalapril, and metoprolol) compared with placebo.

Most common adverse reactions associated with finasteride monotherapy (≥1%) in a 4-year study were impotence decreased libido, decreased volume of ejaculation and rush. Most common adverse reactions (≥2%) associated with tadalafil were headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, and pain in limb.